 | | Vol. 6.02 – 21 January, 2022 |
| |
|
|
| Researchers investigated whether apoptotic cell death and its spatial architecture was linked to tumor molecular heterogeneity using single-cell in situ hybridization analysis.
[Hepatology] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists demonstrated that 3D cultured organoids from fetal and adult human liver with cholangiocyte or hepatocyte phenotype supported hepatitis E virus replication.
[Science Advances] |
|
|
|
| Using hepatocyte-, hepatoblast- and ductal cell-derived organoids, investigators demonstrated that the differentiation defects and lipid alterations were, in part, cell-autonomous.
[Nature Communications] |
|
|
|
| The authors showed that glucagon challenge impaired the expression of HADHA. Liver-specific HADHA overexpression reversed hepatic gluconeogenesis in mice, while HADHA knockdown augmented glucagon response.
[Nature Communications] |
|
|
|
| Three metastasis-associated circRNAs identified in a previous circRNA-sequencing study were screened and validated in two hepatocellular carcinoma (HCC) cohorts. CircRPN2 was downregulated in highly metastatic HCC cell lines and HCC tissues with metastasis.
[Cancer Research] |
|
|
|
| The authors showed that mitochondrial DNA of the normal liver shaped tumor progression, histology, and immune environment prior to the acquisition of oncogenic mutation.
[Cell Reports] |
|
|
|
| Investigators used proteomics and single cell RNA-sequencing analysis to examine the cancer-associated fibroblast landscape in hepatocellular carcinoma.
[Oncogene] |
|
|
|
| Researchers reported the identification of a previously uncharacterized oncogenic signaling pathway in hepatocellular carcinoma that was mediated by the tyrosine kinase Yes.
[Science Signaling] |
|
|
|
| Investigators observed that the increase of Sox9 significantly promoted hepatocellular carcinoma cell growth and invasion in cell cultures, whereas knockdown of Sox9 showed the opposite effects, suggesting that Sox9 may regulate the proliferation and invasion of hepatoma cells in an autocrine manner.
[FEBS Journal] |
|
|
|
| Scientists identified SOCS-7, an inhibitor of cytokine signaling, as a novel regulator of immunosuppression in hepatocellular carcinoma.
[Laboratory Investigation] |
|
|
|
| The authors investigated the effects of hCAP18/LL-37 on hepatocellular carcinoma (HCC) in vitro and in vivo. Results showed that hCAP18/LL-37 overexpression significantly promoted the proliferation of cultured HCC cells and the growth of PLC/PRF-5 xenograft tumor.
[Cell Death Discovery] |
|
|
|
| Investigators determined whether dexmedetomidine might have directly regulated miR-130a/early growth response 1 (EGR1) axis in hepatocellular carcinoma and explored the related mechanisms.
[Cell Death Discovery] |
|
|
|
| By analyzing H3K27ac enrichment and enhancer RNA expression in cultured hepatocellular carcinoma cells, scientists identified six putative MYC enhancer regions.
[Scientific Reports] |
|
|
|
| Investigators determined if patatin-like phospholipase domain-containing protein 3 (PNPLA3), as well as other lipases, transcription factors, or fatty acid (FA)-mediated genes, were regulated by FA mimicking liver lipid accumulation and liver lipid clearing (RECOV) or singular FA physiologically found in dairy cows at 0.5 mM of circulating RECOV.
[Scientific Reports] |
|
|
|
|
| The authors systemically review the diverse interactions of nanomaterials with the liver, specifically on major liver cell types including Kupffer cells, liver sinusoidal endothelial cells, hepatic stellate cells, and hepatocytes as well as the detailed molecular mechanisms involved.
[Advanced Materials] |
|
|
|
| Scientists review the specific functions of several T cell populations involved in NAFLD and NAFLD-driven HCC.
[Hepatology] |
|
|
|
|
| TriSalus Life Sciences® announced a strategic research collaboration with the University of Colorado Anschutz Medical Campus to advance research of immuno-oncology treatments for patients with liver and pancreatic tumors.
[TriSalus Life Sciences®] |
|
|
|
| Ascletis Pharma, Inc. announced the Investigational New Drug (IND) application approval by the US FDA and initiation of global development of ASC22, a first-in-class, subcutaneously administered PD-L1 antibody for functional cure of chronic hepatitis B.
[Ascletis Pharma, Inc.] |
|
|
|
|
| February 6 – 9, 2022
Keystone Resort, Colorado, United States |
|
|
|
|
|
| | NIH National Institute on Alcohol Abuse and Alcoholism – Bethesda, Maryland, United States |
|
|
|
| | UK Research and Innovation – Oxfordshire, England, United Kingdom |
|
|
|
| | University of Copenhagen – Copenhagen, Denmark |
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
| | University of Gothenburg РG̦teborg, Sweden |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
